A particular expression pattern of CD13 epitope 7H5 in chronic lymphocytic leukaemia – a possible new therapeutic target

References

• Taylor A. Aminopeptidases: structure and function. FASEB J. 1993;7:290–8.
   PubMed Web of Science ®Google Scholar
• Antczak C, De Meester I, Bauvois B. Ectopeptidases in pathophysiology. Bioessays. 2001;3:251–60.
   Google Scholar
• Sato Y. Role of aminopeptidase in angiogenesis. Biol Pharm Bull. 2004;27(6):772–6.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1A):363–98.
   PubMed Web of Science ®Google Scholar
• Asmun R, Holmes K, Shapiro L. CD13 (aminopeptidase N) cluster workshop report. In: , Stuart F, Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, (eds.) Leucocyte typing V. New York: Oxford University Press; 1995. p. 771–5.
   Google Scholar
• Kishimoto T, Kikutani H, van dem Borne AEG, Goyert SM, Mason DY, Miyasaka M, et al. (eds.) Leucocyte typing VI. White cell differentiation antigens. New York: Garland Publishing Inc.; 1997. p. 962–3.
   Google Scholar
• Michova А, Guenova M, Nikolova M, Taskov H. CD13 epitope 7H5 exhibits a particular expression pattern in haematological malignancies. Haema. 2003;6(3):336–43.
   Google Scholar
• O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukaemia. Clin Adv Hematol Oncol. 2011;9(1):22–31.
   PubMedGoogle Scholar
• Muller-Hermelink HK, Montserrat E, Catowsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: , Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, (eds.) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: IARC; 2008. p. 180–2.
   Google Scholar
• van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901–28.
   PubMed Web of Science ®Google Scholar
• Dybkaer K, Olesen G, Pedersen FS, Kristensen JS. Stromal-mediated down-regulation of CD13 in bone marrow cells originating from acute myeloid leukaemia patients. Eur J Haematol. 2001;66(3):168–77.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Watson J, Erta E. Flow cytometry. In: , Freshley R, (ed.) Animal cell culture. Oxford: IRL Press; 1992. p. 165–21.
   Google Scholar
• Nakase K, Kita K, Shiku H, Tanaka I, Nasu K, Dohy H, et al. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol. 1996;105(6):761–8.
   PubMed Web of Science ®Google Scholar
• Cocco AE, Osei ES, Thut DM, Edinger AK, Powers JJ, Fu P, et al. Bimodal cell populations are common in chronic lymphocytic leukaemia but do not impact overall survival. Am J Clin Pathol. 2005;123(6):818–25.
   PubMed Web of Science ®Google Scholar
• Pinto A, Del Vecchio L, Carbone A, Roncadin M, Volpe R, Serraino D, et al. Expression of myelomonocytic antigens is associated with unfavourable clinicoprognostic factors in B-cell chronic lymphocytic leukaemia. Ann Oncol. 1991;2(Suppl 2):107–13.
   PubMed Web of Science ®Google Scholar
• Tàssies D, Montserrat E, Reverter JC, Villamor N, Rovira M, Rozman C. Myelomonocytic antigens in B-cell chronic lymphocytic leukaemia. Leuk Res. 1995;19(11):841–8.
   PubMed Web of Science ®Google Scholar
• Bal K, Barcos MP, Stewart C. Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. Am J Clin Pathol. 2003;119(6):824–32.
   PubMed Web of Science ®Google Scholar
• O'Connell P, Gerkis V, D'Aprice A. Variable O-glycosylation of CD13 (aminopeptidase N). J Biol Chem. 1991;266/7:4593–7.
   Web of Science ®Google Scholar
• Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006;26(1):88–130.
   PubMed Web of Science ®Google Scholar
• Luan Y, Xu W. The structure and main functions of aminopeptidase N. Curr Med Chem. 2007;14(6):639–47.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xu W. Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design. Curr Med Chem. 2008;15(27):2850–65.
   PubMed Web of Science ®Google Scholar
• Alaikov T, Konstantinov SM, Tzanova T, Dinev K, Topashka-Ancheva M, Berger MR. Antineoplastic and anticlastogenic properties of curcumin. Ann N Y Acad Sci. 2007;1095:355–70.
   PubMed Web of Science ®Google Scholar
• Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene. 2011;30(28):3139–52.
   PubMed Web of Science ®Google Scholar
• Varalakshmi Ch, Ali AM, Pardhasaradhi BV, Srivastava RM, Singh S, Khar A. Immunomodulatory effects of curcumin: in-vivo. Int Immunopharmacol. 2008;8(5):688–700.
   PubMed Web of Science ®Google Scholar
• Hayun R, Okun E, Berrebi A, Shvidel L, Bassous L, Sredni B, et al. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukaemia cells. Leuk Lymphoma. 2009;50(4):625–32.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukaemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009;15(4):1250–8.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol. 2006;69(1):195–206.
   PubMed Web of Science ®Google Scholar
• Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem. 2010;110(2):447–56.
   PubMed Web of Science ®Google Scholar
• Haque S, Lee H, Waqas B, Chiorazzi N, Mongini P. Anti-inflammatory curcumin inhibits AID expression within cycling human B cells. J Immunol. 2010;184 (Meeting Abstract Supplement):96.21.
   PubMed Web of Science ®Google Scholar
• Angelo LS, Kurzrock R. Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukaemia. Clin Cancer Res. 2009;15(4):1123–5.
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269:199–225.
   PubMed Web of Science ®Google Scholar
• Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7(3):464–73.
   PubMed Web of Science ®Google Scholar